MicroRNA-218 modulates activities of glioma cells by targeting HMGB1

Jianjun Gu1, Rong Xu2, Yaxing Li3

  • 1Department of Neurosurgery, Fuzhou General Hospital, Xiamen University Medical College 156 Road Xi'erhuanbei, Fuzhou 350025, Fujian, P. R. China.

Insights

MicroRNA-218 (miR-218) suppresses glioma progression by downregulating HMGB1 and RAGE. Restoring miR-218 levels inhibits cell proliferation, invasion, and promotes apoptosis in glioma cells.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • Glioma is a primary brain tumor with poor prognosis.
  • MicroRNAs play crucial roles in cancer development and progression.
  • miR-218 is frequently downregulated in glioma, suggesting a tumor-suppressive role.

Purpose of the Study:

  • To investigate the functional role of miR-218 in glioma.
  • To elucidate the underlying molecular mechanism of miR-218 in regulating glioma cell behavior.
  • To explore the potential of targeting the miR-218/HMGB1/RAGE axis for glioma therapy.

Main Methods:

  • Glioma cell lines (U251, U87) were transfected with miR-218 mimics or inhibitors.
  • Gene and protein expression analyzed by qRT-PCR and Western blotting.
  • Cell proliferation, apoptosis, migration, and invasion assessed using MTT, flow cytometry, Transwell, and scratch-wound assays.
  • HMGB1 targeting by miR-218 validated using luciferase reporter assays.

Main Results:

  • miR-218 was significantly downregulated, while HMGB1 was upregulated in glioma cells.
  • miR-218 overexpression inhibited cell viability, colony formation, invasion, and migration, while promoting apoptosis.
  • miR-218 downregulated HMGB1, RAGE, cyclin D1, and MMP-9, and upregulated caspase-9.
  • HMGB1 silencing mimicked some effects of miR-218, while HMGB1 overexpression counteracted miR-218's tumor-suppressive effects.

Conclusions:

  • miR-218 acts as a tumor suppressor in glioma by targeting HMGB1.
  • The miR-218/HMGB1/RAGE pathway regulates glioma cell proliferation, apoptosis, and invasion.
  • Targeting the miR-218-HMGB1-RAGE axis holds potential for novel glioma therapeutic strategies.